•  
  •  
 

Central Asian Journal of Medicine

Abstract

Background. Idiopathic thrombocytopenic purpura (ITP) is a chronic disease which is accompanied with bleeding and decrease in platelet count due to its pathogenesis and treatment. The pathogenetic treatment of ITP is considered to be the use of glucocorticosteroid hormones. Clinical observations indicate that gastrointestinal tract complications such as acute gastritis, duodenitis, gastrointestinal ulcers or exacerbation of previously existing chronic pathologies may occur when patients with ITP take in glucocorticosteroid hormones per os in large doses for a long time. This study was performed to develop prevention methods of stomach and duodenum complications related to hormonal therapy in patients with ITP. Materials and methods. Patients were classified according to the complications of different disorders: gastroduodenitis - 22 (23.1%), gastric ulcers - 6 (6.3%), and duodenal ulcer (or exacerbation of the latter) - 5 (5.3%), exacerbation of colitis - 2 (2.1%), gastrointestinal discomfort - 10 (10.5%), stomach pain -5 (5, 3%). Totally, 50 (52.6%) out of 95 patients with ITP (both adults and children) were registered to have complications of gastrointestinal tract after enteral glucocorticosteroid administration. Findings. It is recommended to transfer corticosteroid administration from per os to the form of inhalation or intravenous one. The relationship between number of platelets and the indication for the performance of an endoscopic examination of gastrointestinal tract along with gastric ulcer hemorrhage has been proven. Endoscopic examination of patients with TP is recommended to be carried out in the stage of clinical remission.

First Page

5

Last Page

28

References

1. Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr. 2010;156 (4):623–8. 2. Nathan D, Ginsburg D, Orkin S, et al. Hematology of Infancy and childhood. 6th Edition . Philadelphia: W.B.Saunder Company ; 2005. pp. 325–345. 3. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83(2):83–89. 4. Avdeev S.N. Delivery device for inhalation drugs used in the treatment of respiratory diseases // Rus. med. journal - 2002. - v.10, No. 5. - P. 37-41. 5. Abdulkadyrov K.M. Idiopathic thrombocytopenic purpura//Clinical Hematology. - St. Petersburg, 2004. - 349-370 p. 6. Andersen J.C. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy // New Engl. J. Med. – 1994. – Vol. 330. – P. 1560-1564 7. Bokarev I.N. Hemorrhagic syndrome // Practical medicine. - M., 2006. –127p. 8. Buchinsky S.N. Advantages of modern inhalation therapy // Rehabilitation and physiotherapy. - Kiev, 2000. –32-38 p. 9. Barkagan Z.S. Hemorrhagic diseases and syndromes. - 2nd ed., Revised. and add. - M .: Medicine, 1988 .-- 528 p. 10. Vakhrushev Y.M., Romanova S.E., Klimentova S.V. Evaluation of the functional state of the stomach during prolonged treatment with prednisone in patients with bronchial asthma // 7th National Congress on Respiratory Diseases. Sat scientific tr - M., 1997.- P.43. 11. Gernsheimer T., McCrae K.R. Immune thrombocytopenic purpura in pregnancy. University of Washington and Puget Sound Blood Center, Seattle, Washington 98104, USA // Curr Opin Hematol. – 2007. – Vol. 14, №5. – P. 574-580. 12. Jacson W.F., Nebulised budesonide therapy // Asthma: Scientific and Practical Review. Oxford, 1995. – P. 1-64. 13. Johnson F.J., Reynolds L.J., Toward T.J. Elastolytic activity and alveolar epithelial type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and rolipram. Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cathays Park, Cardiff, CF10 3XF, UK // Toxicol Appl Pharmacol. – 2005. – Vol. 207, № 3. – P. 257-265. 14. Cines D. B. , Cuker A. , Semple J. W. Pathogenesis of immune thrombocytopenia PresseMed 2014; 43(4 Pt2): e 49-59. Doi:10,1016/jlpm 2014,01,010. 15. Cook D.J., Fuller H.D., Guyatt G.H., et al. Risk factors for gastrointestinal bleeding in critically ill patients: Canadian Crit. Care Trials Groups. // N. Engl. J. Med. – 1994. – Vol. 330. – p. 397–381. 16. Kato A. Disorders associated with autoimmune thrombocytopenic purpura // Nippon Rinsho. – 2003. – Vol. 61. – P. 604-608. 17. Kantorova I., Svoboda P., Scheer P., et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial // Hepatogastroenterology. – 2004. – V. 51, №57. – P. 757–761. 18. Kuter D.J. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Hematology Division, Massachusetts General Hospital, Boston, MA 02114, USA // Europ. J. Haematol. Suppl. – 2008. – Vol. 69. – P. 9-18. 19. Melikiyan A.L. et al. National clinical guidelines for the diagnosis and treatment of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) in adults. Journal of Hematology and Transfusiology. 2017.62 / 1. 24 p. 20. Mikhailov A.P., Danilov A.M., Napalkov A.N., Shulgin V.L. Acute ulcers and erosion of the digestive tract: Textbook // St. Petersburg: publ. –– in St. Petersburg. University, 2004 - 96 p. 21. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. The Scripps Research Institute, La Jolla, CA. rob mcmillan // Semin Hematol. – 2007. – Vol. 44, №4 (Suppl 5). – P. S3-S11. 173. 22. Marchetti F., Bua J., Lazzerini M. Oral or inhaled corticosteroids for the treatment of croup? Letter // Arch. Dis. Child. Educ. Pract. Ed. – 2007. – Vol. 92, №1. – P. 13. 23. Pimanov S.I. Esophagitis, gastritis and peptic ulcer. A guide for doctors. M .: Medical book, 2000.378 p. 24. Zhilin Yu.N. Nebulizer aerosol therapy with the use of the Boreal inhaler: Guidelines for doctors. - M., 2001. –16 p. 25. Neunert, C.E., 2017. Management of newly diagnosed immune thrombocytopenia: can we change outcomes?. Blood advances, 1(24), pp.2295-2301.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.